IND Swift Laboratories LT
NSE: INDSWFTLAB · Pharmaceuticals · sector
₹337.05NSE close 2026-10-26
Key numbers
Market cap₹2,927 cr
Price₹337.05
52w high / low₹425 / ₹87
P/E49.4xSector median 27.9x
P/B2.1xSector median 2.9x
Book value₹159.4
Dividend yield–Sector median 0.48%
ROE4.5%Sector median 11.7%
ROCE5.2%Sector median 12.3%
OPM7.3%Sector median 14.0%
Debt / equity0.01xSector median 0.16x
EV/EBITDA51.7xSector median 18.6x
Interest cover75.3x
Current ratio3.83x
Sales growth 3y-19.0%Sector median +9.6%
Profit growth 3y-4.5%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹442 cr vs borrowings ₹18 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 75.3x in the last 12 months.
- No promoter shares are pledged.
- Promoter holding rose by 3.43 percentage points in a year, to 42.93% (2026-09-30).
- Operating cash flow was below net profit in 3 of the last 5 years (FY26, FY25, FY24).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 96% of net profit in the last 12 months.
- Debtor days went from 48 (FY24) to 113 (FY26).
- No dividend in the last 5 financial years.
- Price ₹337.05 on 2026-10-26: -20.6% from the 52-week high, +286.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹401.25 · low ₹71.91
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 9 | 138 | 153 | 153 | 151 | 170 | 191 |
| EBITDA | -12 | -15 | 207 | 4 | 1 | -2 | 15 | 33 |
| OPM % | -98.6% | -167.8% | 149.5% | 2.4% | 1.0% | -1.1% | 9.1% | 17.3% |
| Other income | 13 | 14 | 4 | 15 | 18 | 28 | 2 | 8 |
| Net profit | 0 | 0 | 222 | 9 | 8 | 10 | 15 | 25 |
| EPS (₹) | 0.07 | 0.00 | 32.96 | 1.28 | 1.00 | 1.17 | 1.81 | 2.84 |
| Revenue YoY | +1,176.3% | +1,641.9% | +22.8% | +25.4% | ||||
| Profit YoY | +1,848.8% | +95,300.0% | -93.2% | +181.4% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1,039 | 1,207 | 1,281 | 562 | 641 | 665 |
| EBITDA | 196 | 203 | 641 | 204 | 34 | 48 |
| Net profit | -2 | 48 | 421 | 250 | 41 | 57 |
| EPS (₹) | -0.36 | 8.06 | 71.24 | 37.25 | 4.95 | 6.82 |
| Revenue growth | +16.2% | +6.1% | -56.1% | +14.2% | +113.3% | |
| Profit growth | – | +785.4% | -40.6% | -83.5% | -75.2% | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -19.0% | -5.6% | +113.3% |
| Net profit | -4.5% | – | -75.2% |
| EPS | -15.0% | – | – |
| Share price | – | +65.4% (2y) | +226.6% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 682 | 931 | 1,173 | 1,384 |
| Borrowings | – | 862 | 17 | 41 | 18 |
| Cash & equivalents | – | 18 | 432 | 467 | 442 |
| Total assets | – | 1,824 | 1,165 | 1,438 | 1,673 |
| Fixed assets | – | 583 | 5 | 260 | 275 |
| Capital work in progress | – | 8 | – | – | 10 |
| Investments | – | 30 | 111 | 174 | 236 |
| Receivables | – | 505 | 169 | 165 | 199 |
| Inventory | – | 439 | 10 | 114 | 148 |
| Payables | – | 204 | 94 | 110 | 146 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 150 | 195 | -181 | -25 | -63 |
| Cash from investing | 5 | -13 | -104 | -110 | -73 |
| Cash from financing | -141 | -186 | 699 | 69 | 142 |
| Capex | 18 | 13 | 45 | 64 | 88 |
| Free cash flow | 132 | 182 | -225 | -90 | -151 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 7.0% | 45.2% | 21.4% | 3.0% |
| ROCE % | – | 11.6% | 66.8% | 21.5% | 3.6% |
| Debtor days | – | 153 | 48 | 107 | 113 |
| Inventory days | – | 244 | 6 | 145 | 191 |
| Payable days | – | 114 | 52 | 140 | 188 |
| Cash conversion cycle (days) | – | 283 | 2 | 112 | 116 |
| Working capital days | – | 240 | 125 | 419 | 411 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 42.93% |
| FIIs | 10.78% |
| DIIs | 0.20% |
| of which Mutual funds | 0.00% |
| of which Insurance | 0.00% |
| Government | 0.00% |
| Public (non-institutions) | 46.09% |
| Quarter | Aug 2025 | Sep 2025 | Dec 2025 | Feb 2026 | Mar 2026 | Jun 2026 | Sep 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 39.50% | 39.50% | 39.50% | 43.06% | 42.99% | 42.93% | 42.93% | 42.93% |
| Promoter group | % |
|---|---|
| Essix Biosciences Limited | 37.81% |
| Navrattan Munjal | 1.16% |
| Rishav Mehta | 1.10% |
| S. R. Mehta | 0.62% |
| Himanshu Jain | 0.55% |
| Gopal Munjal | 0.41% |
| V.R. Mehta | 0.39% |
| Sunita Jain | 0.37% |
| Ravi Mehta | 0.12% |
| Neeta Munjal | 0.11% |
| Nidhi Munjal | 0.10% |
| Meenakshi Mehta | 0.08% |
| Annie Mehta | 0.03% |
| Sahil Munjal | 0.03% |
| Ishav Mehta | 0.01% |
| Public holders above 1% | % |
|---|---|
| Zeal Global Opportunities Fund | 4.62% |
| Nova Global Opportunities Fund PCC - Touchstone | 3.32% |
| Panchkula Finvest Private Limited | 2.48% |
| Ashokkumar Chandak | 2.42% |
| Zaki Abbas Nasser | 2.00% |
| Pranav Joneja | 1.44% |
| ARK Global Emerging Companies, LP | 1.40% |
| Sharwan Singh Guleria | 1.32% |
| Rameshkumar Javerchand Jain | 1.14% |
| Chetan Chandak | 1.04% |
| Nisarg Ajaykumar Vakharia | 1.04% |
| Manish Chandak | 1.01% |
42,667 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| INDSWFTLAB | ₹2,927 cr | 49.4x | 2.1x | 4.5% | 5.2% | 7.3% | -19.0% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-09-24 | Other | Annual General Meeting |
| 2023-09-22 | Other | Annual General Meeting |
| 2022-09-22 | Other | Annual General Meeting |
| 2021-09-23 | Other | Annual General Meeting |
| 2020-09-23 | Other | Annual General Meeting |
| 2019-09-24 | Other | Annual General Meeting |
| 2018-09-19 | Other | Annual General Meeting |
| 2017-09-14 | Other | Annual General Meeting |
| 2016-09-20 | Other | Annual General Meeting |
| 2015-09-18 | Other | Annual General Meeting |
| 2014-09-18 | Other | Annual General Meeting |
| 2013-09-24 | Other | Annual General Meeting |
| 2012-09-21 | Other | Annual General Meeting |
| 2011-09-20 | Dividend | Annual General Meeting And Dividend Re.1/- Per Share |
| 2010-09-16 | Dividend | Annual General Meeting And Dividend Re.1/- Per Share |
| 2009-09-17 | Other | Agm/Div-Rs.1/- Per Share |
| 2008-09-18 | Dividend | Agm/Dividend - 10% |
| 2007-09-21 | Dividend | Agm/Dividend-10% |
| 2006-09-22 | Dividend | Agm/Dividend-15% |
| 2005-09-22 | Dividend | Agm/Dividend-15% |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | INDSWFTLAB |
| BSE code | 532305 |
| ISIN | INE915B01019 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.